The Shuman Law Firm Investigates Retrophin, Inc.

BOULDER, Colo.--(BUSINESS WIRE)--

The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Retrophin, Inc. (“Retrophin” or the “Company”) RTRX. Retrophin is a New York, NY-based company that develops therapies for the treatment of serious, catastrophic or rare diseases.

The Firm's investigation relates to allegations raised in a federal lawsuit which claim that three top Retrophin officers either were fired or stepped down, culminating with the Company's September 30, 2014 announcement that Chief Executive Officer Martin Shkreli was terminated for allegedly engaging in stock irregularities that included granting Retrophin stock outside an approved distribution plan. The complaint also alleges that the defendants caused Retrophin to issue a series of press releases and U.S. Securities and Exchange Commission filings that failed to disclose Mr. Shkreli's stock activity, which allegedly constitutes a violation of Nasdaq listing rules, state and federal law.

If you currently own Retrophin common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at (866) 569-4531or email Mr. Shuman at kip@shumanlawfirm.com or email Mr. Glenn at rusty@shumanlawfirm.com.

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.